Wednesday, June 11, 2025
Behance Facebook Instagram Linkedin Twitter Vimeo VKontakte Youtube
Home 2023

Yearly Archives: 2023

All News

Is Smart for Life (SMFL) $4.30, a Bargain Post Reverse Split?

Editor / Curator -
Psychedelic Stock Review

Is ATAI Live Sciences (ATAI) $2.00, Finally Turning?

Editor / Curator -
Psychedelic Stock Review

The Ketamine Endgame. Silo Pharmaceutical (SILO).

Editor / Curator -
Psychedelic Stock Review

The Ketamine Cure (NY Times)

Editor / Curator -
All News

A Good Bear Market, is a Terrible Thing to Waste. How...

Editor / Curator -
2023 Watch List

The Next Generation Of Mental Health Treatment: Psycheceutical Bioscience Inc.’s Novel...

Editor / Curator -
2022 Watch List

Ardelyx (ARDX) Resubmits New Drug Application to FDA.

Editor / Curator -
Psychedelic Stock Review

Psycheceutical Bioscience Inc.’s (BWVI) Novel Topical Ketamine Delivery.

Editor / Curator -
ARDX, Roland Rick Perry
2022 Watch List

And we Have Another Triple! Ardelyx (ARDX) Touches $5.00, up 333%.

Editor / Curator -
2022 Watch List

Maxim Group Targets 175% Gain in Society Pass (SOPA) to $2.75.

Editor / Curator -
1...121314...18Page 13 of 18

Latest article

Adding Brixton Metals (BBBXF) $0.05 to the Watch List.

All News Editor / Curator -
Having Dinner With Management Tomorrow, We'll be Back With What we Learn. In the meantime, we are adding Brixton Metals (BBBXF) to the Watch...

United States Antimony (UAMY) on Fox News.

All News Editor / Curator -
DALLAS, TX / ACCESS Newswire / June 4, 2025 / United States Antimony Corporation ("USAC," "US Antimony," the "Company"), (NYSE American: UAMY), announced today that its Chairman...

Institutional Analyst: Latest Newsletter.

All News Editor / Curator -
Biotechnology, Beverages, Precious Metals, Psychedelics, and Technology. Perpetua Resources (PPTA) Joins the Billion Dollar Club Launching Institutional Gold Analyst and Gold Investor Conference1. Adding Perpetua Resources...
The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
Contact us: roland@institutionalanalyst.com
© Managed by Revelers.IO Media Group Inc.